Early detection and risk stratification of patients with heart failure (HF) are crucial to improve
outcomes. Given the complexity of the pathophysiological processes of HF and the …

Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality
research indicating its diagnostic and prognostic capabilities, biomarkers are excellent …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Despite considerable improvement in the management of heart failure (HF), unsustainable
levels of morbidity and mortality coupled with an increasing economic and social burden …

Various biological markers are investigated as diagnostic and risk stratification tools for
heart failure (HF). However, there is a large body of evidence that natriuretic peptides (NPs) …

Cardiovascular disease (CVD) is a serious public health concern whose incidence has been
on a rise and is projected by the World Health Organization to be the leading global cause of …

The last decade has seen exciting advances in the field of biomarkers used in managing
patients with heart failure (HF). Biomarker research has broadened our knowledge base …

Heart failure (HF) is the end result of many different cardiac and non-cardiac abnormalities
leading to a complex clinical entity. In this view, the use of biomarkers in HF should be …

Heart failure (HF) is a complex syndrome with high morbidity and mortality while, myocardial
injury, hemodynamic overload, genetic, neurohormonal, inflammatory and biochemical …